BioStock: Respiratorius begins production of VAL001

Respiratorius’ two development projects are running at full speed and a new formulation has been developed for the candidate VAL001. This paves the way for the next step and the company is now starting production for a phase I pharmacokinetic study with the new formulation. BioStock contacted the company’s CEO Johan Drott to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/10/respiratorius-begins-production-of-val001/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se